Clinical Trial Search

Primary: Change From Baseline in Short Term Memory at 6 Months — -0.04; -0.01 Score on a scale — p=0.6931

Primary: Spontaneous Bowel Movement (SBM) Frequency at Week 1 of Administration — 6.7; 5.2 number of SBM per week — p=0.020

Primary: Hemoglobin A1c (HbA1c) - Change From Baseline to End of 3 Month Study Period — -0.99; -0.70; -0.39 percentage of HbA1C

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs): Short Term and Long Term — 1; 5; 5; 9 Participants

Primary: Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Scores. — -31.2; -34.9 units on a scale

Primary: Number of Participants With Cardiac Death and All Myocardial Infarction (MI) (Q-wave and Non-Q Wave) Composite Endpoint — 7 Participants

Primary: Number of Subjects Retained at 6 Months — 11; 4 Participants

Primary: Area Under the Concentration Time Curve of Olodaterol in Plasma Over the Time Interval From 0 to 6 Hours After Drug Administration (AUC0-6)

Primary: Changes From Start of Administration (Week 0) in Pittsburgh Sleep Quality Index (PSQI) Global Score at End of Study — -2; 1; -6 Scores on a Scale

Primary: Hopkins Verbal Learning Test-Revised (HVLT-R) Total Score — 39.40; 36.93; 37.67; 38.37 units on a scale

Primary: The Aim of This Study is to Determine the Effect of Fluticasone/Salmeterol on Sleep Quality in Patients With COPD and to Compare Efficacy of Advair 250 Compared to…

Primary: Number of Unexpected Adverse Events (AEs) — 65 Events

Primary: Time to Recovery of T1 to 10% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration — 4.35; 7.15 Minutes

Primary: Letrozole : AUC0-tz — 2074.71; 2094.63 ng•hr/mL

Primary: Number of Participants With Any Occurrence of Unplanned Re-hospitalization and/or Any Emergency/Urgent Care Visits Within 30 Days of Hospital Discharge — 133; 105…